Effects of fingolimod on functional brain adaptation and clinical measures in multiple sclerosis

Completed

• Conditions: MS; Multiple Sclerose; 10012303

• Registration Number: NL-OMON44409
• Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 70

Inclusion Criteria

- Subjects should be between 18 and 65 years of age
- Subjects should meet the safety criteria to undergo MRI examination
- Patients should be diagnosed with RRMS
- The first measurement of patients on fingolimod should be within four weeks after the start of fingolimod treatment

Exclusion Criteria

- Presence or history of psychiatric or neurological disease (for patients: neurological disease other than MS) that is expected to affect outcome measures (will be discussed with the principal investigator and neurologist)
- Presence or history of drug abuse
- For patients: relapse or steroid treatment less than four weeks prior to examination
- Insufficient visual acuity and motor skills to perform the fMRI task

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>1) Changes in brain activity and brain networks<br /><br>2) Changes in cognition<br /><br>3) Progression of physical disability</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>not applicable</p><br>